| 002508-H | A Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of VAS-101 in Subjects with Stable Sickle Cell Disease | Recruitment has not started | 18-90 Years | NHLBI | | 002443-H | Sickle Cell Disease Stem Cell Mobilization and Apheresis Using Motixafortide | Participants currently recruited/enrolled | 18-65 Years | NHLBI | | 002422-H | In-Depth Molecular Characterization in Marrow Failure Syndromes to Understand Clonal Dynamics and Expansion | Enrolling by Invitation | 2-120 Years | NHLBI | | 002416-H | A Phase IIa Trial of Baricitinib in the Treatment of Kohlmeier-Degos Disease Patients with Neurological Involvement | Participants currently recruited/enrolled | 18-99 Years | NHLBI | | 002352-H | GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejection in Lung Transplantation | Participants currently recruited/enrolled | 18-75 Years | NHLBI | | 002298-H | Platelet Volunteers, Longitudinal and Multi-omic Study | Participants currently recruited/enrolled | 18-100 Years | NHLBI | | 002200-H | Immune Profiling of CLL/SLL Treated with First-Line Pirtobrutinib | Participants currently recruited/enrolled | 18-100 Years | NHLBI | | 001933-H | Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions | Participants currently recruited/enrolled | 10-90 Years | NHLBI | | 001883-H | Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling | Participants currently recruited/enrolled | 18-100 Years | NHLBI | | 001835-H | A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies | Participants currently recruited/enrolled | 18-100 Years | NHLBI | | 001781-H | Thrombosis and Inflammation in Vessels Initiative (TIVI) | Participants currently recruited/enrolled | 5-100 Years | NHLBI | | 001742-H | A Prospective Approach for the Early Detection of Infectious and Noninfectious Lung Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation | Participants currently recruited/enrolled | 5-70 Years | NHLBI | | 001729-H | Evaluation of a Human Milk Oligosaccharide-Based Synbiotic Supplement for Intestinal Microbiota Dysbiosis | Participants currently recruited/enrolled | 18-99 Years | NHLBI | | 001671-H | Correlative Study of Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome | No longer recruiting/follow-up only | 18-100 Years | NHLBI | | 001670-H | A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody(R)-CD3XCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter s Syndrome | No longer recruiting/follow-up only | 18-100 Years | NHLBI | | 001667-H | A Phase I/II Study of the JAK1/2 Inhibitor Ruxolitinib for Relapsed / Refractory Immune Bone Marrow Failure | Participants currently recruited/enrolled | 18-99 Years | NHLBI | | 001635-H | Non-myeloablative Phase I/II Haploidentical HCT Study for Patients with Sickle Cell Disease, Including Compromised Organ Function | No longer recruiting/follow-up only | 4-100 Years | NHLBI | | 001621-H | Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting with Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus | Participants currently recruited/enrolled | 18-120 Years | NHLBI | | 001619-H | A Phase I Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects with Stable Sickle Cell Disease | Participants currently recruited/enrolled | 18-65 Years | NHLBI | | 001565-H | A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease | No longer recruiting/follow-up only | 16-100 Years | NHLBI | | 001528-H | A Phase I/II, Intra-Patient Dose-Escalation Study of the Selective GlyT1 Inhibitor, Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia. | Completed Study; data analyses ongoing | 18-100 Years | NHLBI | | 001522-H | A Phase 1 Single-Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous ZMA001 in Healthy Subjects | Participants currently recruited/enrolled | 18-60 Years | NHLBI | | 001517-H | Single Patient Study of JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease | Completed Study; data analyses ongoing | 18-100 Years | NHLBI | | 001061-H | Observational Study Investigating the Mechanistic Effects of Mitapivat in Subjects with Sickle Cell Disease | No longer recruiting/follow-up only | 16-80 Years | NHLBI | | 000923-H | Observational Study of Cardiac Arrhythmias During Treatment with BTK Inhibitors or Venetoclax | Participants currently recruited/enrolled | 18-110 Years | NHLBI | | 000844-H | Exploring Near Infrared Spectroscopy (NIRS) Technologies for Assessment of Muscle Physiology, Tissue Oxygenation, and Blood Flow in Patients with Sickle Cell Disease (SCD) | Completed Study; data analyses ongoing | 18-100 Years | NHLBI | | 000829-H | Controls and Healthy Vasculature Initiative | Participants currently recruited/enrolled | 18-90 Years | NHLBI | | 000697-H | U01 Cooperative Assessment of Late Effects for SCD Curative Therapies (COALESCE) | Participants currently recruited/enrolled | 18-65 Years | NHLBI | | 000556-H | NHLBI-Emory Advanced Cardiac CT Reconstruction | Recruitment has not started | 18-100 Years | NHLBI | | 000539-H | Addition of JSP191 (c-kit antibody) to Non-myeloablative Hematopoietic Cell Transplantation For Sickle Cell Disease and Beta-Thalassemia | No longer recruiting/follow-up only | 4-100 Years | NHLBI | | 000479-H | Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies | Participants currently recruited/enrolled | 18-100 Years | NHLBI | | 000464-H | Evaluation of Clonal Hematopoiesis in Patients with Sickle Cell Disease Receiving Curative Therapies | Enrolling by Invitation | 4-99 Years | NHLBI | | 000444-H | Vaccine Responses in Patients with B Cell Malignancies | Participants currently recruited/enrolled | 18-90 Years | NHLBI | | 000413-H | Natural History study of CADASIL | Participants currently recruited/enrolled | 18-100 Years | NHLBI | | 000387-H | The Natural History of Acquired and Inherited Bone Marrow Failure Syndromes | Participants currently recruited/enrolled | 2-99 Years | NHLBI | | 000326-H | A Phase 1, Dose Escalation, Safety and Tolerability Study of NX- 2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies | Participants currently recruited/enrolled | 18-100 Years | NHLBI | | 000299-H | Technical Development of Cardiovascular MRI | Participants currently recruited/enrolled | 18-100 Years | NHLBI | | 000272-H | Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults | Completed Study; data analyses ongoing | 5-100 Years | NHLBI | | 000149-H | Pilot Study to Explore the Anti-Inflammatory Effects of Time-Restricted Feeding | Completed Study; data analyses ongoing | 18-80 Years | NHLBI | | 000110-H | A Phase II Study Evaluating Fostamatinib for Hospitalized Adults with COVID-19 | Completed Study; data analyses ongoing | 18-100 Years | NHLBI | | 000070-H | Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study(GENE-FORECAST): Sodium Intervention Trial (SIT)/GENE-FORECAST SIT | Completed Study; data analyses ongoing | 21-65 Years | NHLBI | | 000049-H | Evaluation of the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects with Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat | No longer recruiting/follow-up only | 18-70 Years | NHLBI | | 21-H-0027 | Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens into the Human Lung | Completed Study; data analyses ongoing | 18-64 Years | NHLBI | | 20-H-0158 | Natural History Study: Gene First Approach to Connective Tissue Disease | Completed Study; data analyses ongoing | 2-100 Years | NHLBI | | 20-H-0141 | Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector | No longer recruiting/follow-up only | 18-99 Years | NHLBI | | 20-H-0099 | Data Collection of Standard Care and Evaluation of NHLBI Patients and Donors | Enrolling by Invitation | 2-120 Years | NHLBI | | 20-H-0068 | Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait | Completed Study; data analyses ongoing | 18-80 Years | NHLBI | | 20-H-0049 | NHLBI DIR Cardiovascular Branch PK Papyrus Covered Stent Ethics Oversight of Humanitarian Use Device for Treatment of Acute Perforations of Native Coronary Arteries and Coronary Bypass Grafts in Vessels 2.5 to 5.0 mm in Diameter | Enrolling by Invitation | 18-125 Years | NHLBI | | 20-H-0044 | Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis | Completed Study; data analyses ongoing | 18-80 Years | NHLBI | | 20-H-0033 | Early Initiation of Oral Therapy with Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) | Participants currently recruited/enrolled | 3-99 Years | NHLBI | | 20-H-0029 | An Intravenous, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers | Participants currently recruited/enrolled | 18-99 Years | NHLBI | | 20-H-0021 | Treatment of Refractory Diamond-Blackfan Anemia with Eltrombopag | Completed Study; data analyses ongoing | 2-99 Years | NHLBI | | 19-H-0139 | Investigation of the Natural Progression of Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance. | Participants currently recruited/enrolled | 18-99 Years | NHLBI | | 19-H-0120 | Pilot Study for Geospatial Analysis of Neighborhood Environmental Stress in Relation to Biological Markers of Cardiovascular Health and Health Behaviors in Women | Participants currently recruited/enrolled | 19-45 Years | NHLBI | | 19-H-0118 | Repeat Peripheral Blood Stem Cell Transplantation for Patients with Sickle Cell Disease or Beta-Thalassemia and Falling Donor Myeloid Chimerism Levels | Participants currently recruited/enrolled | 2-80 Years | NHLBI | | 19-H-0111 | Early Clonal Dynamics During Venetoclax Treatment for Chronic Lymphocytic Leukemia (CLL) | Participants currently recruited/enrolled | 18-85 Years | NHLBI | | 19-H-0100 | Best Noninvasive Predictor of Renal Function in Assessing Adult Sickle Nephropathy | Completed Study; data analyses ongoing | 18-125 Years | NHLBI | | 19-H-0097 | A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Multiple Oral Doses of AG-348 in Subjects with Stable Sickle Cell Disease | Completed Study; data analyses ongoing | 18-70 Years | NHLBI | | 19-H-0088 | NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study | Completed Study; data analyses ongoing | 21-99 Years | NHLBI | | 19-H-0057 | Multiple Patient Program for Lamprene(R) (clofazimine) for the treatment of Non-Tuberculous Mycobacterial (NTM) Infections- CLAM320B2002M | Participants currently recruited/enrolled | 18-99 Years | NHLBI | | 19-H-0001 | Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients that are Treatment Na(SqrRoot) ve or Receiving Bruton s-tyrosine Kinase Inhibitor (BTK-I) Therapy | Completed Study; data analyses ongoing | 18-100 Years | NHLBI | | 18-H-0146 | Genotype -Phenotype Correlation of PKLR Variants with Pyruvate Kinase, 2,3-Diphosphglycerate and ATP Activities in Red Blood Cells of Patients with Sickle Cell Disease | Participants currently recruited/enrolled | 18-80 Years | NHLBI | | 18-H-0118 | Technical and Translational Development of Cardiovascular MRI (CMR) | Participants currently recruited/enrolled | 7-100 Years | NHLBI | | 18-H-0108 | Vascular Disease Discovery Protocol | Participants currently recruited/enrolled | 2-100 Years | NHLBI | | 18-H-0090 | Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH using Peripheral Blood Stem Cells and post-transplant Cyclophosphamide for GVHD Prophylaxis | Participants currently recruited/enrolled | 4-75 Years | NHLBI | | 18-H-0019 | Effect of Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults | Participants currently recruited/enrolled | 18-99 Years | NHLBI | | 18-H-0012 | A Phase I Study of HERV-E TCR Transduced Autologous T Cells in Patients with Metastatic Clear Cell Renal Cell Carcinoma | No longer recruiting/follow-up only | 18-75 Years | NHLBI | | 18-H-0011 | Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System | Participants currently recruited/enrolled | 18-100 Years | NHLBI | | 18-H-0004 | Low Dose Danazol for the Treatment of Telomere Related Diseases | Participants currently recruited/enrolled | 3-99 Years | NHLBI | | 18-H-0003 | Discovery of Sirolimus Sensitive Biomarkers in Blood | Completed Study; data analyses ongoing | 18-90 Years | NHLBI | | 17-H-0162 | Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments: A Multi-Level, Community-Based Physical Activity Intervention | Participants currently recruited/enrolled | 21-75 Years | NHLBI | | 17-H-0146 | Prospective Multicenter Registry On Radiation Dose Estimates of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI) | Completed Study; data analyses ongoing | 18-100 Years | NHLBI | | 17-H-0121 | Eltrombopag for Patients with Fanconi Anemia | No longer recruiting/follow-up only | 6-99 Years | NHLBI | | 17-H-0118 | A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | Completed Study; data analyses ongoing | 18-100 Years | NHLBI | | 17-H-0095 | Heart Catheterization Using Magnetic Resonance Imaging (MRI) Fluoroscopy and Passive Guidewires | Clinical hold/Recruitment or enrollment suspended | 18-100 Years | NHLBI | | 17-H-0091 | Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS using CordIn, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, to Expedite Engraftment and Improve Transplant Outcome | Participants currently recruited/enrolled | 4-75 Years | NHLBI | | 17-H-0069 | Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease | No longer recruiting/follow-up only | 2-100 Years | NHLBI | | 17-H-0056 | Pathophysiology of Acute Pain in Patients with Sickle Cell Disease | Completed Study; data analyses ongoing | 18-80 Years | NHLBI | | 17-H-0019 | A Randomized Trial of Sirolimus (Rapamune(R)) for Relapse Prevention in Patients with Severe Aplastic Anemia Responsive to Immunosuppressive Therapy | No longer recruiting/follow-up only | 2-99 Years | NHLBI | | 16-H-0144 | Impact of Elastin Mediated Vascular Stiffness on End Organs | Completed Study; data analyses ongoing | 3-85 Years | NHLBI | | 16-H-0132 | CADASIL Disease Discovery | Completed Study; data analyses ongoing | 18-100 Years | NHLBI | | 16-H-0074 | Williams Syndrome (WS) and Supravalvar Aortic Stenosis (SVAS) DNA and Tissue Bank | Completed Study; data analyses ongoing | 0-85 Years | NHLBI | | 16-H-0063 | Williams Syndrome Skin and Vascular Elasticity Study (WS-SAVE Study) | Completed Study; data analyses ongoing | 1-70 Years | NHLBI | | 16-H-0019 | High Image Matrix CT Reconstruction | Completed Study; data analyses ongoing | 18-99 Years | NHLBI | | 15-H-0190 | Human Biospecimen Procurement and Analysis to Support Translational Research to Identify Genetic Etiology and Disease Mechanism(s) in Rare Genetic Vascular/Cardiovascular Diseases | Participants currently recruited/enrolled | 0-100 Years | NHLBI | | 15-H-0172 | A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | No longer recruiting/follow-up only | 18-125 Years | NHLBI | | 15-H-0155 | Hereditary Parkinson Disease Natural History Protocol | Completed Study; data analyses ongoing | 18-80 Years | NHLBI | | 15-H-0024 | Genes Involved in Lipid Disorders | Completed Study; data analyses ongoing | 2-99 Years | NHLBI | | 15-H-0016 | A Phase II Study Using ACP-196 in Patients with Relapsed/Refractory and Treatment Naive Deletion 17p CLL/SLL: Pharmacodynamic Assessment of BTK Inhibition and Anti-Tumor Response. | Completed Study; data analyses ongoing | 18-100 Years | NHLBI | | 14-HG-0048 | Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST) | Completed Study; data analyses ongoing | 21-65 Years | NHLBI | | 14-H-0188 | Prospective Evaluation of Next Generation CT Reconstruction | Participants currently recruited/enrolled | 18-99 Years | NHLBI | | 14-H-0077 | Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia in Individuals with Higher Risk of Transplant Failure | No longer recruiting/follow-up only | 4-80 Years | NHLBI | | 13-H-0194 | Inflammatory Characterization of Known or Possible Cardiovascular Diseases | Completed Study; data analyses ongoing | 18-100 Years | NHLBI | | 13-H-0183 | Cardiovascular Health and Needs Assessment in Washington D.C. - Development of a Community-Based Behavioral Weight Loss Intervention | Participants currently recruited/enrolled | 19-85 Years | NHLBI | | 13-H-0116 | A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients | Participants currently recruited/enrolled | 4-99 Years | NHLBI | | 13-H-0065 | Human Translational Studies of Inflammation and Cardiometabolic Diseases: The Psoriasis, Atherosclerosis and Cardiometabolic Disease (PACI) Initiative | Completed Study; data analyses ongoing | 18-99 Years | NHLBI | | 13-H-0060 | Analysis of Samples Collected from a Subject who Received ACP- 501 (Human Recombinant Lecithin:Cholesterol Acyltransferase [rhLCAT]) | Completed Study; data analyses ongoing | 18-100 Years | NHLBI | | 13-H-0059 | Longitudinal Observational Study of Severe Asthma | Completed Study; data analyses ongoing | 18-100 Years | NHLBI | | 13-H-0051 | Bronchodilator Effects of Nebulized versus Inhaled Albuterol in Subjects with Lymphangioleiomyomatosis | Participants currently recruited/enrolled | 18-100 Years | NHLBI | | 12-H-0150 | Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia | No longer recruiting/follow-up only | 2-99 Years | NHLBI | | 12-H-0141 | Prospective Evaluation of New Techniques in Radiation Reduction for Cardiovascular Computed Tomographic Angiography | Participants currently recruited/enrolled | 18-100 Years | NHLBI | | 12-H-0092 | An Intravenous, Open-Label, Single-Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of rhLCAT in Patients with Stable Coronary Artery Disease | Completed Study; data analyses ongoing | 30-75 Years | NHLBI | | 12-H-0064 | A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications | Participants currently recruited/enrolled | 4-75 Years | NHLBI | | 12-H-0035 | A Phase II study of Ibrutinib for Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and are Older than 65 or have a 17p Deletion | No longer recruiting/follow-up only | 18-125 Years | NHLBI | | 11-H-0209 | Male Hormones for Telomere Related Diseases | Completed Study; data analyses ongoing | 2-99 Years | NHLBI | | 11-H-0046 | Cross-Sectional Characterization of Idiopathic Bronchiectasis | Completed Study; data analyses ongoing | 18-100 Years | NHLBI | | 10-H-0154 | Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused with a Reduced Dose of Non-Mobilized Donor T-Cells | Participants currently recruited/enrolled | 4-80 Years | NHLBI | | 10-H-0126 | Cardiovascular Disease Discovery Protocol | Participants currently recruited/enrolled | 1-100 Years | NHLBI | | 10-H-0083 | A Phase I Trial of Safety and Immunogenicity of Gardasil Vaccination Post Stem Cell Transplantation in Patients with and without Immunosuppression | Completed Study; data analyses ongoing | 18-50 Years | NHLBI | | 09-H-0239 | Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees at Baseline, and After Immunization with the H1N1 or Seasonal Influenza Vaccines | Completed Study; data analyses ongoing | 18-125 Years | NHLBI | | 09-H-0225 | Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia | No longer recruiting/follow-up only | 2-100 Years | NHLBI | | 09-H-0172 | Natural History of Bronchiectasis | Participants currently recruited/enrolled | 5-100 Years | NHLBI | | 08-H-0186 | Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity with Bortezomib | Completed Study; data analyses ongoing | 18-70 Years | NHLBI | | 08-H-0105 | Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) | Participants currently recruited/enrolled | 18-110 Years | NHLBI | | 08-H-0046 | Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated with Severe Neutropenia Refractory to Immunosuppressive Therapy | Completed Study; data analyses ongoing | 4-75 Years | NHLBI | | 07-H-0142 | Research Respiratory Tract Procedures | Participants currently recruited/enrolled | 5-100 Years | NHLBI | | 07-H-0113 | Procurement and Analysis of Blood, Bone Marrow, and Buccal Mucosa Samples from Healthy Volunteers to Support Clinical and Translational Research Projects in the NHLBI | Participants currently recruited/enrolled | 8-99 Years | NHLBI | | 07-H-0005 | Pilot Study of Topical Dexamethasone 0.01% Solution for Prevention of Oral Chronic Graft Versus Host Disease | Completed Study; data analyses ongoing | 12-110 Years | NHLBI | | 06-H-0217 | Genetic Disorders of Mucociliary Clearance | Completed Study; data analyses ongoing | 2-65 Years | NHLBI | | 06-H-0190 | Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders with Alemtuzumab (Campath) | Completed Study; data analyses ongoing | 18-85 Years | NHLBI | | 06-H-0072 | Atorvastatin as a Disease Modifying Agent in Stage II and III Pulmonary Sarcoidosis: A Randomized, Double-Blind, Placebo-Controlled Trial | Completed Study; data analyses ongoing | 18-70 Years | NHLBI | | 05-H-0130 | Long-Term Evaluation and Follow Up Care of Patients Treated with Allogeneic Stem Cell Transplants | Participants currently recruited/enrolled | 7-80 Years | NHLBI | | 04-H-0161 | Studies of the Natural History of Sickle Cell Disease | Participants currently recruited/enrolled | 2-90 Years | NHLBI | | 04-H-0012 | Collection of Blood, Bone Marrow, Urine, and/or Tissue Samples from Patients with Solid Tumors, Hematological Malignancies or Non-Malignant Hematologic Disorders or HLA Compatible Family Members | Participants currently recruited/enrolled | 2-100 Years | NHLBI | | 03-H-0280 | Disease Pathogenesis and Natural History of Lipid Disorders | Participants currently recruited/enrolled | 2-100 Years | NHLBI | | 03-H-0170 | Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease (SCD) and B-Thalassemia | No longer recruiting/follow-up only | 2-80 Years | NHLBI | | 03-H-0105 | The Determination of Genetic Basis Of Immunodeficiency | Participants currently recruited/enrolled | 0-99 Years | NHLBI | | 03-H-0015 | Human Specimen Collection to Support Basic and Clinical Research | Enrolling by Invitation | 18-100 Years | NHLBI | | 01-H-0088 | Determining the Prevalence and Prognosis of Secondary Pulmonary Hypertension in Adult Patients with Sickle Cell Anemia | Completed Study; data analyses ongoing | 18-125 Years | NHLBI | | 00-H-0051 | Cutaneous Tumorigenesis in Patients with Tuberous Sclerosis | Participants currently recruited/enrolled | 18-90 Years | NHLBI | | 99-H-0076 | Asthma Sample Collection Protocol | Completed Study; data analyses ongoing | 18-75 Years | NHLBI | | 99-H-0050 | Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients with Debilitating Hematologic Diseases | Completed Study; data analyses ongoing | 2-80 Years | NHLBI | | 97-H-0041 | Screening Protocol for Subjects Being Evaluated for National Heart, Lung and Blood Institute (NHLBI) Protocols | Enrolling by Invitation | 2-100 Years | NHLBI | | 96-H-0100 | Role of Genetic Factors in the Pathogenesis of Lung Disease | Participants currently recruited/enrolled | 2-90 Years | NHLBI | | 96-H-0049 | Use of Granulocyte Colony Stimulating Factor (G-CSF) Mobilized Leukapheresis Collections from Healthy Volunteers to Develop Improved Methods of Stem Cell and Lymphocyte Selection for Allogeneic Transplantation | Participants currently recruited/enrolled | 18-60 Years | NHLBI | | 95-H-0186 | Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM) | Participants currently recruited/enrolled | 16-100 Years | NHLBI | | 85-H-0105 | Cardiovascular Evaluation of Homozygous Familial Hypercholesterolemia | Completed Study; data analyses ongoing | 2-70 Years | NHLBI | | 79-H-0100 | Teaching Protocol for the Evaluation of Plasma Lipoproteins | Completed Study; data analyses ongoing | 2-99 Years | NHLBI | | 76-H-0051 | Lipoprotein Metabolism in Normal Volunteers and Hyperlipoproteinemic Patients | Completed Study; data analyses ongoing | 18-80 Years | NHLBI | |